Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Chief Scientific Officer | December 26, 2025 | December 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date December 26, 2025 · Filed December 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 140,002 |
Reported balance
After 2025-12-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-26 · Sale · Disposed 90,000 · Balance 140,002 F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $39.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $39.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2025 Filed Dec 30, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | SaleCommon Stock | 90,000 | $38.74 | $3,486,600.00 |
DisclosureSEC source: 0001193125-25-337049 · ownership.xml · nonDerivative · entry 1 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,002 F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $39.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $39.45 | $0.00 |
DisclosureSEC source: 0001193125-25-326776 · ownership.xml · derivative · entry 4 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-12-17 F5 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | Tax withholdingCommon Stock | 139,998 | $39.45 | $5,522,921.10 |
DisclosureSEC source: 0001193125-25-326776 · ownership.xml · nonDerivative · entry 3 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,002 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 320,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326776 · ownership.xml · nonDerivative · entry 2 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,000 F2 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs"). Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326776 · ownership.xml · nonDerivative · entry 1 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:58 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0000950170-25-009263 · ownership.xml · derivative · entry 1 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:36 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000950170-24-007436 · ownership.xml · derivative · entry 1 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 20:52 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $13.63 | $0.00 |
DisclosureSEC source: 0000899243-23-005141 · doc4.xml · derivative · entry 1 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 22:40 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $4.94 Strike: $7.60 | $1,235,800.00 |
DisclosureSEC source: 0000899243-22-003465 · doc4.xml · derivative · entry 1 Robinson John Edward · CIK 0001856514 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.